FDA Determines Regulatory Review Period for Kaletra Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for Kaletra, a prescription medication, in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).